These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31549414)

  • 41. Peptide binding specificities of HLA-B*5701 and B*5801.
    Zhang Y; Mei H; Wang Q; Xie J; Lv J; Pan X; Tan W
    Sci China Life Sci; 2012 Sep; 55(9):818-25. PubMed ID: 23015131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Avidity determines T-cell reactivity in abacavir hypersensitivity.
    Adam J; Eriksson KK; Schnyder B; Fontana S; Pichler WJ; Yerly D
    Eur J Immunol; 2012 Jul; 42(7):1706-16. PubMed ID: 22585534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
    Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
    Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
    Arnedo Valero M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
    Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY
    Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.
    Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T
    Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA.
    Yun J; Adam J; Yerly D; Pichler WJ
    Allergy; 2012 Nov; 67(11):1338-46. PubMed ID: 22943588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study.
    Van Den Driessche G; Fourches D
    J Cheminform; 2017; 9():13. PubMed ID: 28303164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TARC/CCL17 Expression Is Associated with CD8
    Gao Y; Kuwahara S; Kazaoka A; Ito K; Aoki S
    Biol Pharm Bull; 2022; 45(9):1347-1353. PubMed ID: 36047204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions.
    Illing PT; Mifsud NA; Purcell AW
    Curr Opin Immunol; 2016 Oct; 42():31-40. PubMed ID: 27261882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury.
    Monshi MM; Faulkner L; Gibson A; Jenkins RE; Farrell J; Earnshaw CJ; Alfirevic A; Cederbrant K; Daly AK; French N; Pirmohamed M; Park BK; Naisbitt DJ
    Hepatology; 2013 Feb; 57(2):727-39. PubMed ID: 22987284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms leading to T-cell activation in drug hypersensitivity.
    Meng X; Yerly D; Naisbitt DJ
    Curr Opin Allergy Clin Immunol; 2018 Aug; 18(4):317-324. PubMed ID: 29905574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and immunogenetic correlates of abacavir hypersensitivity.
    Phillips EJ; Wong GA; Kaul R; Shahabi K; Nolan DA; Knowles SR; Martin AM; Mallal SA; Shear NH
    AIDS; 2005 Jun; 19(9):979-81. PubMed ID: 15905681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.